![](https://ophthalmologybreakingnews.com/files/images/blog_outlook-therapeutics-receives-uk-approval-of-lytenava-for-wet-amd-treatment.jpg)
Outlook Therapeutics Receives UK Approval of Lytenava for Wet AMD Treatment
Outlook Therapeutics announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (AMD) in the UK. Lytenava …